About GeNEWityTM
Genewity B.V. is a recently founded biotech company based in Leiden, the Netherlands. Closely collaborating with the LUmc, we build on successes of our scientific and business teams in cell and gene therapies.
GenewityTM has been founded to commercialize another potentially groundbreaking therapy for developing autologous thymus tissue de novo. GenewityTM is currently in a preclinical development stage and is engaged in raising a Series A to push the technology to the clinic.
Genewity is a partner in the PRO-THYMUS Eureka Eurostars 3 Programme. Please visite the Eureka website for more information.
Genewity has been selected for funding under the European Innovation Council (EIC) Accelerator program.
Our team members
Arno Bisschop, PhD, MD.
Chief Executive Officer
Prof. Dr. Frank Staal
Chief Scientific Advisor
Prof. Dr. Eric Claassen
Chief Scientific Officer
Max Renes, MPhil, MSc.
Chief Operating Officer
Conny Kruyssen
Chief Financial Officer
Rob Posthumus, LL.M.
Chief Legal Officer
Jelle Feddema, MSc.
Head of Business Dev.
Drs. Johan Renes
Intellectual Property Strategy Advisor
Hadil Es-Sbai, MSc.
Clinical Development Advisor
Linda van de Burgwal, PhD.
Advisor